Articles related to SURGICAL ONCOLOGY

Perioperative apalutamide plus ADT, six months before and after radical prostatectomy, achieved a ninefold improvement in major pathologic response and a 20% reduction in metastasis-free survival events versus placebo plus ADT in patients with high-risk localized or locally advanced prostate cancer in a phase 3 trial.

Neoadjuvant apalutamide plus abiraterone and ADT before radical prostatectomy was associated with improved 12-month potency recovery and lower positive surgical margin rates compared with surgery alone in a small phase 2 trial of men with high-risk localized prostate cancer.

The ABCDE warning signs help spot melanoma early, so counsel your patients regarding Asymmetry, Border, Color, Diameter, and Evolving (the mole or spot changes in size, shape, or color. It may also start to bleed, itch, or crust).

“Patients treated in the Optune Pax arm had a median time to pain progression of 15.2 months compared to 9.1 months.” — PANOVA-3 Trial, FDA Approval Announcement

Statistical models incorporating individual clinical and tumor characteristics showed superior accuracy when validated against standardized clinical trial data compared to retrospective prediction tools.

The modified Johns Hopkins procedure demonstrates how robotic assistance can enhance surgical precision through small incisions, potentially reducing trauma and accelerating recovery in suitable pancreatic cancer patients.